Claims for Patent: 9,944,898

Summary for Patent: 9,944,898

Title:	Method of generating tumor-specific T cells
Abstract:	A method for the expansion of tumor-specific T-cells includes obtaining an enriched population of T-cells from a subject with cancer; and contacting the enriched population of T-cells ex-vivo with: (i) an anti-CD3 antibody, an anti-CD28 antibody, and/or functional fragments thereof, and (ii) a VEGF inhibitor, to activate and expand the T-cells.
Inventor(s):	Kim; Julian (Cleveland, OH), Graor; Hallie (Cleveland, OH), Zhang; Mei (Cleveland, OH), Visioni; Anthony (Cleveland, OH)
Assignee:	Case Western Reserve University (Cleveland, OH)
Application Number:	14/205,069
Patent Claims:	1. A method for the expansion of tumor-specific CD4+ helper and/or CD8+ T-cells, the method comprising: obtaining an enriched population of T-cells from tumor draining lymph nodes of the subject; and contacting the enriched population of T-cells ex-vivo with: (i) an anti-CD3 antibody, an anti-CD28 antibody, and/or functional fragments thereof, and (ii) a VEGF inhibitor, at amounts effective to activate and expand the T-cells. 2. The method of claim 1, further comprising contacting the enriched population of T-cells ex-vivo with at least one substance having agonistic activity towards an IL-2 receptor. 3. The method of claim 2, wherein the at least one substance having agonistic activity towards an IL-2 receptor is IL-2. 4. The method of claim 1, wherein the VEGF-inhibitor is selected from neutralizing monoclonal antibodies against VEGF or its receptor, small molecule tyrosine kinase inhibitors of VEGF receptors, soluble VEGF receptors which act as decoy receptors for VEGF and ribozymes which specifically target VEGF mRNA or combinations thereof. 5. The method of claim 4, wherein the neutralizing monoclonal antibodies against VEGF is bevacizumab. 6. The method of claim 1, further comprising obtaining the enriched population of T-cells by identifying lymph nodes draining the tumor in the subject and resecting one or more of the lymph nodes from the subject. 7. The method of claim 6, wherein the resected lymph nodes are cryopreserved after resection and then thawed prior to obtain an enriched population of T-cells. 8. The method of claim 7, wherein the resected lymph nodes are cultured with IL-2 prior to cryopreservation. 9. The method of 1, wherein the activated and expanded T-cell population is washed, and resuspended in a solution that does not include a VEGF-inhibitor for infusion into the subject.

Details for Patent 9,944,898

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2033-03-11